Voriconazole: A New Triazole Antifungal Agent
Top Cited Papers
- 1 March 2003
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (5) , 630-637
- https://doi.org/10.1086/367933
Abstract
The 1990s witnessed an expansion of the antifungal armamentarium to include 2 new azole agents, fluconazole and itraconazole. These agents changed our approach to treating many fungal infections. However, neither was an ideal agent. Itraconazole was plagued by absorption problems; fluconazole had a limited spectrum of antifungal activity, and resistance was soon noted in immunosuppressed hosts who received long-term treatment. Second-generation triazole agents have been in development for the past decade. The first of these new agents to receive approval from the US Food and Drug Administration (FDA) is voriconazole, a synthetic derivative of fluconazole. Replacement of one of the triazole rings with a fluorinated pyrimidine and the addition of an α-methyl group resulted in expanded activity, compared with that of fluconazole. The development of voriconazole proceeded primarily because of this broadened antifungal spectrum.Keywords
This publication has 46 references indexed in Scilit:
- Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver MicrosomesAntimicrobial Agents and Chemotherapy, 2002
- Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation RegimensAntimicrobial Agents and Chemotherapy, 2002
- Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patientsClinical Pharmacology & Therapeutics, 2002
- Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: a Dose Escalation StudyThe Journal of Clinical Pharmacology, 2002
- Review of the safety and efficacy of voriconazoleExpert Opinion on Investigational Drugs, 2002
- International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance ProgramJournal of Clinical Microbiology, 2001
- In Vitro Activities of Four Novel Triazoles against Scedosporium sppAntimicrobial Agents and Chemotherapy, 2001
- In Vitro Fungicidal Activities of Voriconazole, Itraconazole, and Amphotericin B against Opportunistic Moniliaceous and Dematiaceous FungiJournal of Clinical Microbiology, 2001
- In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenemJournal of Antimicrobial Chemotherapy, 1999
- In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin BJournal of Antimicrobial Chemotherapy, 1998